Firma Kuros Biosciences, Autor bei Presse-Blog

Kuros Biosciences to present at upcoming clinical and investor conferences

10. März 2021 Firma Kuros BiosciencesForschung und Entwicklungbone, cervical, extender, Gold, implant, kuros, magnetos, market, osseous, patients, posterolateral, statements, vitoss, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two major European conferences in March, both to be held virtually. Mehr

Kuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe

2. März 20214. März 2021 Firma Kuros BiosciencesFirmeninternaxis, bone, cells, clinical, Gold, graft, implants, kuros, magnetos, orthobiologics, research, spinal, statements, with, wound

Agreements in Netherlands, Switzerland and Austria and letter of intent in Finland Supports further acceleration of sales of MagnetOs bone graft Kuros Biosciences (SIX: KURN) today announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering Mehr

Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week

20. November 20204. März 2021 Firma Kuros BiosciencesMedizintechnikbone, chf, clinical, fibrin, forward, graft, growth, has, its, kuros, looking, magnetos, pth, spinal, statements

. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 International Life Science Award Kuros Biosciences (SIX: KURN) today announced that it has won the 2020 Mehr

Kuros announces results of Rights Offering

20. Oktober 20204. März 2021 Firma Kuros BiosciencesForschung und Entwicklungbone, chf, extender, fibrin, implant, kuros, magnetos, market, osseous, posterolateral, prospectus, pth, securities, statements, with

Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of its Rights Offering, first announced on October 5, 2020, in which a total of up to 8,426,229 newly registered shares of Kuros with a nominal value of CHF Mehr

Kuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting

6. Oktober 20204. März 2021 Firma Kuros BiosciencesMedizintechnikbone, fibrin, fuse, implant, kuros, magnetos, market, osseous, patients, posterolateral, pth, statements, vitoss, with, wound

Kuros Biosciences today announced it will unveil new research on the role of osteoimmunology in bone formation in three presentations at the North American Spine Society (NASS) 2020 Annual Meeting, held virtually, October 6-9. Kuros is a leader in next Mehr

Kuros Biosciences reports MagnetOs products approved in Australia

5. Oktober 20204. März 2021 Firma Kuros BiosciencesFirmeninternautograft, bone, cells, Gold, graft, kuros, magnetos, market, patients, putty, research, spinal, statements, with, wound

MagnetOs Granules and MagnetOs Putty receive TGA approval in Australia Initial launch of MagnetOs on the Australian market scheduled for late Q1 2021. Kuros Biosciences BV, the Dutch subsidiary of Kuros Biosciences AG (SIX: KURN), today announced that MagnetOs Granules Mehr

Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing

1. Oktober 20204. März 2021 Firma Kuros BiosciencesForschung und Entwicklungbone, cancer, extender, fibrin, Gold, implant, kuros, magnetos, mds, osseous, patients, posterolateral, pth, statements, with

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, will host an expert perspectives webinar on pioneering solutions for targeted and controlled bone healing on Wednesday, October 14, 2020 at 2pm Central European Time (CET). The call Mehr

Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft

21. September 20204. März 2021 Firma Kuros BiosciencesForschung und Entwicklungbone, cells, extender, Gold, implant, kuros, magnetos, orthobiologics, osseous, patients, posterolateral, putty, statements, with, wound

Strong adoption by spinal surgeons since U.S. launch in September 2019 Sales accelerating with over 2,000 patients treated to date Kuros Biosciences (SIX: KURN) today announced that over 2,000 patients have been treated worldwide with its MagnetOs bone graft, an Mehr

Kuros Convenes Extraordinary General Meeting

11. September 20204. März 2021 Firma Kuros BiosciencesFinanzen / Bilanzenautograft, bone, cells, chf, egm, fibrin, Gold, kuros, magnetos, patients, pth, spinal, statements, with, wound

Kuros Biosciences (SIX: KURN) today announced that it will hold an Extraordinary General Meeting (EGM) of shareholders to seek approval to increase the Company’s ordinary share capital. The EGM will be held at Kuros Biosciences AG, Wagistrasse 25, 8952 Schlieren, Mehr

Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH

1. September 20204. März 2021 Firma Kuros BiosciencesForschung und Entwicklungautograft, bone, ddd, fibrin, Flowable, graft, kuros, market, patients, posterolateral, pth, spinal, statements, tlif, with

First investigational trial of a drug-biologic bone graft for spine fusion Phase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograft Primary endpoint is radiographic interbody fusion at 12 months Potential to address a major commercial opportunity Kuros Mehr

Autor: Firma Kuros Biosciences